Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions

Roche logo

Roche

Status

Conditions

Cancers With NTRK, ROS1, or ALK Gene Fusions

Treatments

Drug: Entrectinib

Study type

Expanded Access

Funder types

Industry

Identifiers

NCT03066661
Entrectinib (RXDX-101) - EAP

Details and patient eligibility

About

Expanded access to entrectinib will be given to patients with cancers harboring NTRK1/2/3, ROS1, or ALK gene fusions who do not qualify for participation in, or who are otherwise unable to access, an ongoing clinical trial for entrectinib.

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Diagnosis of advanced cancer with an NTRK1, NTRK2, NTRK3, ROS1, or ALK gene fusion
  • Unable to participate in an ongoing entrectinib (RXDX-101) clinical trial
  • Willing and able to provide written, signed informed consent
  • Medically suitable for treatment with entrectinib (RXDX-101)

Exclusion criteria

Currently enrolled in an ongoing clinical study with any other investigational agent

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems